Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2438]

Hard to drug: Protein droplets reveal new ways to inhibit transcription factors in an aggressive form of prostate cancer

Hard to drug: Protein droplets reveal new ways to inhibit transcription factors in an aggressive form of prostate...

Research finds correlation between biomarker HSD3B1 and resistance to combined hormone therapy and radiotherapy

Research finds correlation between biomarker HSD3B1 and resistance to combined hormone therapy and radiotherapy

FDA approves enzalutamide for non-metastatic castration-sensitive prostate cancer with biochemical recurrence

FDA approves enzalutamide for non-metastatic castration-sensitive prostate cancer with biochemical recurrence

Treatment strategy for certain advanced prostate cancers shows promise in preclinical models

Treatment strategy for certain advanced prostate cancers shows promise in preclinical models

Association of molecular subtypes in bladder cancer with response to neoadjuvant chemotherapy, progression, and survival

Association of molecular subtypes in bladder cancer with response to neoadjuvant chemotherapy, progression, and...

Precision medicine improves survival outcomes for patients with metastatic castration-resistant prostate cancer with BRCA gene alterations

Precision medicine improves survival outcomes for patients with metastatic castration-resistant prostate cancer...

Bone scans overstage prostate cancer at initial staging compared with PSMA PET

Bone scans overstage prostate cancer at initial staging compared with PSMA PET

187 new genetic variants linked to prostate cancer

187 new genetic variants linked to prostate cancer

ESMO 2023: Lutetium (177Lu) vipivotide tetraxetan shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive mCRPC in the pre-taxane setting

ESMO 2023: Lutetium (177Lu) vipivotide tetraxetan shows clinically meaningful and highly statistically significant...

ESMO 2023: Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimus

ESMO 2023: Kidney cancer study shows improved outcomes for patients with advanced disease when treated with...

More from ecancer